Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

LDL cholesterol has been identified as the primary therapeutic target for lipid management to reduce the future risk of coronary events. Despite the use of LDL cholesterol-targeted therapy with statins and other lipid-altering agents, many patients still suffer coronary events. Residual risk for such events has been attributed, at least in part, to persistently elevated atherogenic particle concentration. When patients are found to have elevated non-HDL cholesterol, ApoB-100 or LDL particle concentrations, they are presumed to be at increased risk and are often prescribed more aggressive lipid-altering therapy. This review examines the evidence that these biomarkers provide additional clinically useful information both in coronary risk prediction and in lipid management decision-making.

Original languageEnglish (US)
Pages (from-to)69-79
Number of pages11
JournalClinical Lipidology
Volume8
Issue number1
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Keywords

  • ApoB
  • LDL particle concentration
  • LDL particle number
  • biomarkers for coronary heart disease
  • coronary heart disease risk prediction
  • non-HDL cholesterol

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment'. Together they form a unique fingerprint.

  • Cite this